Geneva, Switzerland and Boston, MA -December 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today announced that company management will participate in the BMO Prescriptions for Success Healthcare Conference on December 14th, 2017, in New York City.
ObsEva's presentation will take place on Thursday, December 14th, 2017, at 3.00 p.m. Eastern Time (ET). A webcast will be available in the "Investors" section of ObsEva's website www.ObsEva.com.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
[email protected]
+1 202-955-6222 x2526
Company Contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Mario Corso
Senior Director, Investor Relations
[email protected]
+1 781-366-5726
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c8567854-1956-4005-ac07-72b7f4767671


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Instagram Outage Disrupts Thousands of U.S. Users
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 



